Consolidation therapy for ovarian cancer

Gloria S. Huang, Gary L. Goldberg, Abbie L. Fields

Research output: Contribution to journalArticle

Abstract

Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalWomen's Oncology Review
Volume5
Issue number1
DOIs
StatePublished - Mar 2005

Fingerprint

Ovarian Neoplasms
Radiotherapy
Therapeutics
Survival
Poisons
Biological Factors
Paclitaxel
Platinum
Publications
Catheters
Quality of Life
Radiation
Recurrence
Drug Therapy
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Huang, G. S., Goldberg, G. L., & Fields, A. L. (2005). Consolidation therapy for ovarian cancer. Women's Oncology Review, 5(1), 3-8. https://doi.org/10.1080/14733400500070708

Consolidation therapy for ovarian cancer. / Huang, Gloria S.; Goldberg, Gary L.; Fields, Abbie L.

In: Women's Oncology Review, Vol. 5, No. 1, 03.2005, p. 3-8.

Research output: Contribution to journalArticle

Huang, GS, Goldberg, GL & Fields, AL 2005, 'Consolidation therapy for ovarian cancer', Women's Oncology Review, vol. 5, no. 1, pp. 3-8. https://doi.org/10.1080/14733400500070708
Huang, Gloria S. ; Goldberg, Gary L. ; Fields, Abbie L. / Consolidation therapy for ovarian cancer. In: Women's Oncology Review. 2005 ; Vol. 5, No. 1. pp. 3-8.
@article{59ee741c9df7459c86a8512aa33eb5dc,
title = "Consolidation therapy for ovarian cancer",
abstract = "Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.",
author = "Huang, {Gloria S.} and Goldberg, {Gary L.} and Fields, {Abbie L.}",
year = "2005",
month = "3",
doi = "10.1080/14733400500070708",
language = "English (US)",
volume = "5",
pages = "3--8",
journal = "Women's Oncology Review",
issn = "1473-3404",
publisher = "Parthenon Publishing Group",
number = "1",

}

TY - JOUR

T1 - Consolidation therapy for ovarian cancer

AU - Huang, Gloria S.

AU - Goldberg, Gary L.

AU - Fields, Abbie L.

PY - 2005/3

Y1 - 2005/3

N2 - Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.

AB - Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.

UR - http://www.scopus.com/inward/record.url?scp=22944437773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944437773&partnerID=8YFLogxK

U2 - 10.1080/14733400500070708

DO - 10.1080/14733400500070708

M3 - Article

AN - SCOPUS:22944437773

VL - 5

SP - 3

EP - 8

JO - Women's Oncology Review

JF - Women's Oncology Review

SN - 1473-3404

IS - 1

ER -